Gilead Sciences Inc. (GILD: Quote) Monday said U.S Food and Drug Administration has accepted the supplemental New Drug Application and granted a six-month priority review for once-daily Truvada to reduce the risk of HIV-1 infection among uninfected adults.
Truvada was approved by the FDA in 2004 for the treatment of HIV-1 infection and is currently the most-prescribed antiretroviral treatment in the United States.
The FDA grants priority review status to drug candidates that provide major advances in treatment or provide a treatment where no adequate therapy exists.
Truvada is not currently indicated to reduce the risk of HIV infection.
Click here to receive FREE breaking news email alerts for Gilead Sciences Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com